Pfizer Launches Phase III Trial for Non-Small Cell Lung Cancer

September 24, 2009
Pfizer Oncology announced that it will initiate a global, Phase III clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.